Skip to main content
VCbacked
Log inGet Started

Sensorium Therapeutics

Boston, United States

Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.

$25.0M raised
Aug 2025
Series A
Health CareMedicalTherapeutics

Top Investors

Sante VenturesHatteras Venture PartnersMission BioCapitalPalo Santo FundRoute 66 Ventures

Founder Contacts

30,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Sensorium Therapeutics

How much funding has Sensorium Therapeutics raised?
Sensorium Therapeutics has raised $25.0M in total funding. The most recent round was Series A. The last funding was announced in August 2025.
Who are Sensorium Therapeutics's investors?
Sensorium Therapeutics's investors include Sante Ventures, Hatteras Venture Partners, Mission BioCapital, Palo Santo Fund, Route 66 Ventures.
Where is Sensorium Therapeutics headquartered?
Sensorium Therapeutics is headquartered in Boston, United States.
What does Sensorium Therapeutics do?
Sensorium Therapeutics is a drug discovery platform that develops novel FDA-approved psychoactive medicines.
What stage is Sensorium Therapeutics at?
Sensorium Therapeutics is at the Series A stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Sensorium Therapeutics — Funding & Investors." VCBacked, August 29, 2025, https://www.vcbacked.co/company/sensorium-therapeutics. Accessed July 2, 2026.
APA
VCBacked. (2025). Sensorium Therapeutics — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/sensorium-therapeutics
Wikipedia (cite web)
{{cite web |title=Sensorium Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sensorium-therapeutics |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Health Care

View all
Oryl Photonics
Lausanne
Allterum Therapeutics
Houston$1.0M
OncoRevive
Brunswick$119K
Rapport Therapeutics
Boston$250.0M
YLAH
Bern$589K
Novostia
Epalinges$6.6M